BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang S, Cai C, Wang H, Ma X, Shao A, Sheng J, Yu C. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-021-00796-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang D, Zhang Y, Wang Y, Xu F, Liang J, Wang W. Diagnostic accuracy and prognostic significance of Glypican-3 in hepatocellular carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12:1012418. [DOI: 10.3389/fonc.2022.1012418] [Reference Citation Analysis]
2 Khan SA, Lee TKW. Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking. Front Pharmacol 2022;13:968148. [DOI: 10.3389/fphar.2022.968148] [Reference Citation Analysis]
3 Sathiyaseelan A, Saravanakumar K, Wang MH. Cerium oxide decorated 5-fluorouracil loaded chitosan nanoparticles for treatment of hepatocellular carcinoma. Int J Biol Macromol 2022:S0141-8130(22)01316-2. [PMID: 35750101 DOI: 10.1016/j.ijbiomac.2022.06.112] [Reference Citation Analysis]